Short answer
Eton Pharmaceuticals, Inc. (ETON) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 results announced for quarter ended September 30, 2026.
Eton Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 results announced for quarter ended September 30, 2026
- Press release attached as Exhibit 99.1, containing the underlying financial results
- Adjusted EBITDA highlighted as management’s key non-GAAP operating metric
- Adjusted EBITDA used for budgeting, strategy evaluation, acquisition review and investor communications
- Investors should review the exhibit for GAAP results, adjusted EBITDA and reconciliation details
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $57.9M, up 158% YoY, driven by HEMANGEOL and broad portfolio growth
- Adjusted EBITDA $28.5M, or 49% margin, versus 13% prior year, signaling substantial operating leverage
- 2026 guidance raised to revenue above $175M and Adjusted EBITDA margin at least 40%
- GAAP EPS $1.06 benefited from a $12.9M deferred-tax valuation allowance release; non-GAAP EPS $0.50 better reflects operations
- Pipeline catalysts include KHINDIVI PDUFA date May 28, 2027, LIBERVANT PDUFA date March 29, 2027, and planned launches in 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Eton Pharmaceuticals, Inc. 8-K filings
Get the next ETON 8-K as it lands
Follow ETON for push alerts, or ask the research agent what this filing means.